Subscribe for email alerts

Don’t miss a single Science & Enterprise post. Sign up for our daily email alerts.

Follow us on Twitter

  • National Cancer Institute is funding research on using programmable synthetic messenger RNA to treat two types of s… https://t.co/kYyOAY6MOf
    about 8 hours ago
  • New post on Science and Enterprise: NIH Funds Programmable mRNA to Treat Cancer https://t.co/DKptaY956d #Science #Business
    about 8 hours ago
  • Attn @ArcticFisheries .. Why Migraine Sufferers May Want to Eat More Fish https://t.co/3AaUvjuNqT
    about 12 hours ago
  • Drug maker Sanofi is purchasing biotechnology company Translate Bio, a developer of messenger RNA vaccines and ther… https://t.co/iJUJA00PmY
    about 1 day ago
  • New post on Science and Enterprise: Sanofi Acquires mRNA Developer in $3.2B Deal https://t.co/lRVt9pv3bq #Science #Business
    about 1 day ago

Please share Science & Enterprise

Biotech Opens Gene Therapy Manufacturing Facility

Adeno-associated virus

A biotechnology company serving gene therapy developers is opening a manufacturing facility for engineered viruses that deliver gene therapies. . . . → Read More: Biotech Opens Gene Therapy Manufacturing Facility

Covid-19 Delta Variant Testing Reference Released

Covid-19 testing

A company designing synthetic DNA and RNA says reference materials are available for tests that detect the quickly spreading Covid-19 delta variant. . . . → Read More: Covid-19 Delta Variant Testing Reference Released

Synthetic Blood Vessel Maker Gains $2.2M in Seed Funds

Red blood cells illustration

A start-up company creating synthetic blood vessels for transplants, based on research in materials science and cell biology, is raising $2.2 million in seed funds. . . . → Read More: Synthetic Blood Vessel Maker Gains $2.2M in Seed Funds

ALS Drug Maker Gains $135M in New Funds

Man in wheelchair

A developer of treatments for people with amyotrophic lateral sclerosis, or ALS, is raising $135 million in its third venture financing round. . . . → Read More: ALS Drug Maker Gains $135M in New Funds

Pooled Saliva Tests Detect Covid-19 in Schools

Preparing classrooms for students return

Combining commercial saliva tests to speed detection of the SARS-CoV-2 virus in schools is shown as accurate as individual gold-standard nasal swab tests. . . . → Read More: Pooled Saliva Tests Detect Covid-19 in Schools

Trial to Test Antibody Drug for Alzheimer’s Prevention

Neurons

Eli Lilly and Company is partnering with an Alzheimer’s disease research center to test a synthetic antibody for preventing the disorder in at-risk individuals. . . . → Read More: Trial to Test Antibody Drug for Alzheimer’s Prevention

Immune Cell Cancer Biotech Gains $172M in New Funds

Natural killer cell

A biotechnology company developing cancer therapies with natural killer cells in the immune system is raising $172 million in its second venture round. . . . → Read More: Immune Cell Cancer Biotech Gains $172M in New Funds

$60M Challenge Seeks RNA Bio-Production Network

Gene therapy graphic

A new challenge competition aims to build a distributed network of facilities to design, develop, and manufacture RNA-based biologic products. . . . → Read More: $60M Challenge Seeks RNA Bio-Production Network

Precision Gene-Editing Biotech Gains $200M in New Funds

David Liu

A biotechnology company says it discovers therapies with the gene-editing technique Crispr to carry out a wider range of precise genomic corrections. . . . → Read More: Precision Gene-Editing Biotech Gains $200M in New Funds

Trial Underway for Crispr Lymphoma Therapy

Crispr-Cas9

A clinical trial enrolled its first participant testing the safety of a treatment for lymphoma, a type of cancer, using the gene-editing technique Crispr. . . . → Read More: Trial Underway for Crispr Lymphoma Therapy